

# ACT Onco<sup>®</sup> + Report

PATIENT		
Identifier: 洪魁恩		Patient ID: 48812186
Date of Birth: Jun 01, 1988		Gender: Male
Diagnosis: Prostate high grade undifferentiated sarcoma		
ORDERING PHYSICIAN		
Name: 張延驊醫師		Tel: 886-228712121
Facility: 臺北榮總		
Address: 臺北市北投區石牌路二段 201 號		
SPECIMEN		
Specimen ID: S11129483H		Collection site: Prostate
Date received: Nov 02, 2022		Type: FFPE tissue
Lab ID: AA-22-06603		D/ID: NA

## ABOUT ACT Onco<sup>®</sup>+

The test is a next-generation sequencing (NGS)-based assay developed for efficient and comprehensive genomic profiling of cancers. This test interrogates coding regions of 440 genes associated with cancer treatment, prognosis and diagnosis. Genetic mutations detected by this test include small-scale mutations like single nucleotide variants (SNVs), small insertions and deletions (InDels) ( $\leq 15$  nucleotides) and large-scale genomic alterations like copy number alterations (CNAs). The test also includes an RNA test, detecting fusion transcripts of 13 genes.

## SUMMARY FOR ACTIONABLE VARIANTS

### VARIANTS/BIOMARKERS WITH EVIDENCE OF CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Probable Effects in Patient's Cancer Type		Probable Sensitive in Other Cancer Types
	Sensitive	Resistant	
Not detected			

### VARIANTS/BIOMARKERS WITH POTENTIAL CLINICAL SIGNIFICANCE

Genomic Alterations/Biomarkers	Possibly Sensitive	Possibly Resistant
SMARCA4 R978*	Tazemetostat	-
PTEN Homozygous deletion	Olaparib, Rucaparib	Erlotinib, Gefitinib, Cetuximab, Panitumumab, Trastuzumab

#### Note:

- The above summary tables present genomic variants and biomarkers based on the three-tiered approach proposed by US FDA for reporting tumor profiling NGS testing. "Variants/biomarkers with evidence of clinical significance" refers to mutations that are widely recognized as standard-of-care biomarkers (FDA level 2/AMP tier 1). "Variants/biomarkers with potential clinical significance" refers to mutations that are not included in the standard of care but are informational for clinicians, which are commonly biomarkers used as inclusion criteria for clinical trials (FDA level 3/AMP tier 2).
- The therapeutic agents and possible effects to a given drug are based on mapping the variants/biomarkers with ACT Genomics clinical knowledge database. The mapping results only provide information for reference, but not medical recommendation.
- Please refer to corresponding sections for more detailed information about genomic alteration and clinical relevance listed above.

# ACTOnco<sup>®</sup> + Report

## TESTING RESULTS

### VARIANT(S) WITH CLINICAL RELEVANCE

#### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Allele Frequency
SMARCA4	R978*	39.3%

#### - Copy Number Alterations

Chromosome	Gene	Variation	Copy Number
Chr10	PTEN	Homozygous deletion	0
Chr11	ATM, CHEK1, MRE11	Heterozygous deletion	1
Chr4	FBXW7	Heterozygous deletion	1

#### - Fusions

Fusion Gene & Exon	Transcript ID
No fusion gene detected in this sample	

#### - Immune Checkpoint Inhibitor (ICI) Related Biomarkers

Biomarker	Results
Tumor Mutational Burden (TMB)	3.8 muts/Mb
Microsatellite Instability (MSI)	Microsatellite stable (MSS)

#### Note:

- Loss of heterozygosity (LOH) information was used to infer tumor cellularity. Copy number alteration in the tumor was determined based on 80% tumor purity.
- For more therapeutic agents which are possibly respond to heterozygous deletion of genes listed above, please refer to APPENDIX for more information.
- TMB was calculated by using the sequenced regions of ACTOnco<sup>®</sup> to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The threshold for high mutation load is set at  $\geq 7.5$  mutations per megabase. TMB, microsatellite status and gene copy number deletion cannot be determined if calculated tumor purity is  $< 30\%$ .

# ACT Onco<sup>®</sup> + Report

## THERAPEUTIC IMPLICATIONS TARGETED THERAPIES

Genomic Alterations	Therapies	Effect
<b>Level 3B</b>		
<i>PTEN</i> Homozygous deletion	Olaparib, Rucaparib	<b>sensitive</b>
<i>SMARCA4</i> R978*	Tazemetostat	<b>sensitive</b>
<b>Level 4</b>		
<i>PTEN</i> Homozygous deletion	Erlotinib, Gefitinib, Cetuximab, Panitumumab, Trastuzumab	<b>resistant</b>

Therapies associated with benefit or lack of benefit are based on biomarkers detected in this tumor and published evidence in professional guidelines or peer-reviewed journals.

Level	Description
<b>1</b>	FDA-recognized biomarkers predictive of response or resistance to FDA approved drugs in this indication
<b>2</b>	Standard care biomarkers (recommended by the NCCN guideline) predictive of response or resistance to FDA approved drugs in this indication
<b>3A</b>	Biomarkers predictive of response or resistance to therapies approved by the FDA or NCCN guideline in a different cancer type
<b>3B</b>	Biomarkers that serve as inclusion criteria for clinical trials (minimal supportive data required)
<b>4</b>	Biomarkers that show plausible therapeutic significance based on small studies, few case reports, or preclinical studies

# ACT Onco<sup>®</sup> + Report

## IMMUNE CHECKPOINT INHIBITORS (ICIs)

No genomic alterations detected to confer sensitivity or lack of benefit to immune checkpoint therapies.

### - Other Biomarkers with Potential Clinical Effects for ICIs

Genomic Alterations	Potential Clinical Effects
Not detected	

Note: Tumor non-genomic factors, such as patient germline genetics, PDL1 expression, tumor microenvironment, epigenetic alterations or other factors not provided by this test may affect ICI response.

## CHEMOTHERAPIES

Genomic Alterations	Therapies	Effect	Level of Evidence	Cancer Type
<b>SMARCA4</b> R978*	Cisplatin Vinorelbine	<b>Sensitive</b>	Clinical	Lung cancer
	Cyclophosphamide Doxorubicin	<b>Less sensitive</b>	Clinical	Breast cancer

## HORMONAL THERAPIES

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to hormonal therapies.

## OTHERS

No genomic alterations detected in this tumor predicted to confer sensitivity or lack of benefit to other therapies.

### Note:

Therapeutic implications provided in the test are based solely on the panel of 440 genes sequenced. Therefore, alterations in genes not covered in this panel, epigenetic and post-transcriptional and post-translational factors may also determine a patient's response to therapies. In addition, several other patient-associated clinical factors, including but not limited to, prior lines of therapies received, dosage and combinations with other therapeutic agents, patient's cancer types, sub-types, and/or stages, may also determine the patient's clinical response to therapies.

# ACT Onco<sup>®</sup> + Report

## VARIANT INTERPRETATION

### SMARCA4 R978\*

#### Biological Impact

The SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a, member 4 (SMARCA4) gene encodes an ATP-dependent helicase, a catalytic subunit of the SWI/SNF chromatin remodeling complex which play a role in gene transcription, DNA synthesis and DNA repair<sup>[1][2][3]</sup>. SMARCA4 has been implicated as a haploinsufficient gene as demonstrated by the development of mammary tumors in SMARCA4 heterozygous mice<sup>[4]</sup>. SMARCA4 is the most frequently mutated gene among the SWI/SNF subunits and its inactivation has been implicated in malignant rhabdoid tumors, lymphoma, medulloblastoma, lung and ovarian cancer<sup>[5][6][7]</sup>. Germline mutations in the SMARCA4 gene predispose carriers to pediatric atypical teratoid/ rhabdoid tumors (AT/RT)<sup>[6][7][8]</sup> and small cell carcinoma of the ovary of hypercalcemic type (SCCOHT)<sup>[9][10][11]</sup>.

R978\* mutation results in a premature truncation of the SMARCA4 protein at amino acid 978 (UniProtKB). This mutation is predicted to lead to a loss of SMARCA4 function, despite not having characterized in the literature.

#### Therapeutic and prognostic relevance

Results of in vitro and in vivo preclinical models showed that SMARCA2- and SMARCA4-deficient small-cell carcinoma of the ovary hypercalcemic type (SCCOHT) were sensitive to the inhibitor of the H3K27 histone methyltransferase (EZH2), tazemetostat<sup>[12]</sup>. Clinical trials are underway to evaluate the efficacy of tazemetostat in patients with SMARCA4 loss or mutation (NCT03155620, NCT03213665, and NCT02601950).

Low SMARCA4 expression is a significant prognostic biomarker to predict increased sensitivity to cisplatin and vinorelbine combination chemotherapy in non-small cell lung cancer (NSCLC) patients<sup>[13]</sup>. Loss or reduced expression of SMARCA4 and SMARCB1 in triple-negative breast cancer (TNBC) cell lines and patients correlated with poor response to doxorubicin-containing regimen (doxorubicin and cyclophosphamide)<sup>[14]</sup>.

### ATM Heterozygous deletion

#### Biological Impact

The ataxia-telangiectasia mutated protein kinase (ATM) gene encodes a PI3K-related serine/threonine protein kinase involved in genomic integrity maintenance and plays central roles in DNA double-strand break (DSB) repair, which can be induced by ionizing radiation, chemotherapy drugs, or oxidative stress<sup>[15]</sup>. ATM is a well-characterized tumor suppressor gene, hereditary mutations and haploinsufficiency of ATM result in markedly increased susceptibility to a variety of cancer types<sup>[16][17][18][19][20]</sup>. Results from a case-cohort study of colorectal cancer and cancer-free control individuals suggested that germline pathogenic mutations in ATM and PALB2 should be added to established CRC risk genes as part of standard tumor genetic testing panels<sup>[21]</sup>. ATM is among the most commonly aberrant genes in sporadic cancers. Somatic ATM aberrations are frequently observed in hematologic malignancies<sup>[22][23][24][25]</sup> and a broad range of tumors such as prostate cancer<sup>[26]</sup>, head and neck squamous cell carcinoma (HNSCC)<sup>[27]</sup>, pancreatic cancer<sup>[28]</sup>, lung adenocarcinoma<sup>[29]</sup>, breast cancer<sup>[30]</sup>, and ovarian cancer<sup>[17]</sup>.

#### Therapeutic and prognostic relevance

In May 2020, the U.S. FDA approved olaparib for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, and progressed following prior treatment with enzalutamide or abiraterone acetate (NCT02987543)<sup>[31]</sup>.

In a phase II trial (TOPARP-A; NCT01682772), 3 out of 4 metastatic prostate cancer patients harboring only ATM inactivating mutations responded to olaparib treatment<sup>[32]</sup>. Also, the phase II TOPARP-B trial (NCT01682772) demonstrated that olaparib treatment resulted in a RECIST 1.1 or PSA50 response rate of 10.5% (2/12) and a

# ACT Onco<sup>®</sup> + Report

composite overall response rate of 36.8% (7/19) in prostate cancer patients harboring deleterious ATM mutations<sup>[33]</sup>. In another randomized, double-blind phase II trial in Asian patients with metastatic gastric cancer has shown that addition of olaparib to paclitaxel significantly increased the OS in both the overall population and patients with low or undetectable ATM protein expression (NCT01063517)<sup>[34]</sup>. However, in the subsequent phase III trial (GOLD; NCT01924533), addition of olaparib to paclitaxel did not significantly improve OS in the overall or the ATM-negative population of Asian gastric cancer patients<sup>[35]</sup>. Besides, in a phase II trial (TBCRC 048; NCT03344965), 7 metastatic breast cancer patients harboring only ATM mutations were not responded to olaparib treatment (SD: n=2, PD: n=5)<sup>[36]</sup>. In a phase II trial (TRITON2; NCT02952534), 49 mCRPC patients harboring ATM alteration had limited response to rucaparib treatment. The radiographic response rate was 10.5 % (n=2/19 evaluable patients), the prostate-specific antigen response rate was 4.1% (n=2/49), and the 6-month clinical benefit rate was 28.6% (n=12/42)<sup>[37]</sup>.

In preclinical studies, cells with ATM alternation were sensitive to olaparib, niraparib, and talazoparib treatment in vitro and in vivo<sup>[38][39][40][41]</sup>.

In addition, ATM has been determined as an inclusion criterion for the trials evaluating olaparib efficacy in breast cancer (NCT04053322) and advanced solid tumors (NCT03297606), rucaparib efficacy in ovarian cancer (NCT01968213)<sup>[42]</sup> and prostate cancer (NCT02952534, NCT03533946)<sup>[37]</sup>, niraparib efficacy in pancreatic cancer (NCT03553004, NCT03601923), prostate cancer (NCT02854436), melanoma (NCT03925350), metastatic esophageal/gastroesophageal junction (GEJ)/proximal gastric adenocarcinoma (NCT03840967), and any malignancy, except prostate (NCT03207347), and talazoparib efficacy in advanced or metastatic cancer (NCT02286687), HER2-negative solid tumors (NCT02401347), prostate cancer (NCT03148795), and lung cancer (NCT03377556), respectively.

Also, a prospective study in muscle-invasive bladder cancer patients suggested that genomic alternations in the DNA repair genes ATMs, RB1 and FANCC could be recognized as biomarkers predictive of response to cisplatin-based neoadjuvant chemotherapy<sup>[43]</sup>. However, loss-of-function of the ATM-CHEK2-TP53 cascade is associated with resistance to anthracycline/mitomycin-containing chemotherapy in patients with breast cancer<sup>[44]</sup>.

A retrospective study of VICTOR trial demonstrated that ATM loss was associated with worse prognosis in colorectal cancer<sup>[45]</sup>.

## CHEK1 Heterozygous deletion

### Biological Impact

The checkpoint kinase 1 (CHEK1 or CHK1) gene encodes a protein kinase involved in transducing DNA damage signals and is required for both the intra-S phase and G2/M checkpoints<sup>[46]</sup>. CHEK1 heterozygosity has been shown to cause haploinsufficient phenotypes that can contribute to tumorigenesis through inappropriate S phase entry, accumulation of DNA damage during replication, and failure to restrain mitotic entry<sup>[47][48]</sup>. Despite acting as a tumor suppressor, homozygous loss-of-function mutations in CHEK1 have not been identified in tumors<sup>[49]</sup>, and CHEK1 mutations are extremely rare<sup>[46]</sup>. Overexpression of CHEK1 has been observed in a variety of tumors, including liver cancer<sup>[50]</sup>, breast cancer<sup>[51]</sup>, colorectal cancer<sup>[52]</sup>, non-small cell lung (NSCLC) cancer<sup>[53]</sup>, and nasopharyngeal cancer<sup>[54]</sup>.

### Therapeutic and prognostic relevance

In May 2020, the U.S. FDA approved olaparib for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in homologous recombination repair (HRR) genes, including BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L, and progressed following prior treatment with enzalutamide or abiraterone acetate (NCT02987543)<sup>[31]</sup>.

In addition, CHEK1 has been determined as an inclusion criterion for the trials evaluating olaparib efficacy in advanced solid tumors (NCT03297606; CAPTUR trial), rucaparib efficacy in ovarian cancer (NCT01968213)<sup>[42]</sup>, prostate cancer (NCT03533946), niraparib efficacy in pancreatic cancer (NCT03553004), and any malignancy, except prostate



# ACT Onco<sup>®</sup> + Report

(NCT03207347), and talazoparib efficacy in lung cancer (NCT03377556), respectively.

Selective inhibitors for CHEK1 and CHEK2 alone or in combination with other agents are currently being investigated in clinical trials<sup>[55]</sup>.

## **FBXW7 Heterozygous deletion**

### **Biological Impact**

The F-box/WD repeat-containing protein 7 (FBXW7) gene encodes a protein that belongs to the SCF (SKP1-CUL1-F-box protein) E3 ligase complex. FBXW7 is recognized as a tumor suppressor which is involved in the negative regulation of oncogenes such as c-Myc<sup>[56][57]</sup>, c-Jun<sup>[58]</sup>, cyclin E<sup>[59]</sup>, Notch family members<sup>[60][61]</sup>, Aurora-A<sup>[62]</sup>, mTOR<sup>[63]</sup>, KLF5<sup>[64]</sup>, and MCL-1<sup>[65]</sup>. Inactivating FBXW7 mutation or copy number loss may result in the accumulation of oncoproteins and therefore lead to malignant transformation<sup>[66]</sup>. FBXW7 is a haploinsufficient tumor suppressor gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological functions<sup>[64][65][67]</sup>.

### **Therapeutic and prognostic relevance**

Clinical efficacy of mTOR inhibitors was seen in patients harboring aberrations in the FBXW7 gene (one patient with refractory fibrolamellar hepatocellular carcinoma, and one patient with lung adenocarcinoma)<sup>[68][69]</sup>. Moreover, in vitro assay also suggested that loss or inactivation of FBXW7 may confer sensitivity to mTOR inhibitor<sup>[63]</sup>.

Preclinical studies suggested that mutations or loss of FBXW7 were associated with regorafenib and oxaliplatin resistance in CRC cell lines and gefitinib resistance in lung cancer cells<sup>[70][71][72][73]</sup>.

Retrospective studies have indicated that a relatively low expression level of FBXW7 is an independent prognostic marker of poor survival for patients with hepatocellular carcinoma, lung adenocarcinoma and squamous cell carcinoma<sup>[74][72]</sup>.

## **MRE11 Heterozygous deletion**

### **Biological Impact**

The MRE11 gene encodes a protein that forms the MRE11-RAD50-NBS (MRN) complex involved in sensing and repairing DNA double-strand breaks via homologous recombination and non-homologous end joining<sup>[75][76]</sup>. MRE11 has been implicated as a haploinsufficient gene with one copy loss may lead to weak protein expression and is insufficient to execute its original physiological function<sup>[75]</sup>. The carrier of MRE11 mutation may confer elevated risks for numerous types of cancers including breast cancer, ovarian cancer, endometrial cancer, colorectal cancer, and lymphoid cancer<sup>[75][76][77][78][79][80][81]</sup>.

### **Therapeutic and prognostic relevance**

In a Phase II clinical trial (n=50), one castration-resistant prostate cancer patient harboring an MRE11 inactivating mutation responded to olaparib<sup>[32]</sup>. Preclinically, loss of MRE11 also predicted sensitivity to PARP inhibitor talazoparib and ABT-888 in endometrial cancer<sup>[82]</sup> and microsatellite unstable colorectal cancer (CRC) cell lines<sup>[83]</sup>. MRE11 has been selected as an inclusion criterion for the trial examining olaparib in metastatic biliary tract cancer (NCT04042831), and talazoparib in HER2-negative breast cancer (NCT02401347) and prostate cancer (NCT03148795).

CRC patients with tumor deficient of MRE11 showed initially reduced disease-free survival (DFS) and overall survival (OS) but improved long-term DFS and OS compared with patients with an intact MRE11<sup>[84]</sup>.

# ACT Onco<sup>®</sup> + Report

## PTEN Homozygous deletion

### Biological Impact

The phosphatase and tensin homolog deleted on chromosome ten (PTEN) gene encodes a lipid/protein phosphatase that is important for the regulation of cell proliferation, survival, homologous recombination and maintenance of genomic integrity<sup>[85][86]</sup>. PTEN acts as an essential tumor suppressor by antagonizing the PI3K/AKT/mTOR signaling pathway<sup>[87]</sup>. PTEN is a haploinsufficient tumor suppressor gene, in which having only one copy of the wild-type allele does not produce enough protein product to execute wild-type functions<sup>[88][89][90]</sup>. Germline loss-of-function PTEN mutations are found in approximately 80% of patients with Cowden syndrome, a disorder that is associated with high-penetrance breast and thyroid cancer<sup>[91][92][93]</sup>. Somatic mutations or monoallelic loss of PTEN is regularly observed in a significant fraction of human cancers, including sporadic breast cancer, colon cancer, endometrial cancer, prostate cancer, and glioblastoma<sup>[94][95][96][97][98]</sup>.

### Therapeutic and prognostic relevance

Somatic loss of PTEN results in aberrant activation of PI3K/AKT/mTOR signaling pathway and provides a mechanistic rationale for PI3K pathway inhibitors treatment<sup>[99][100]</sup>. Preclinical studies demonstrated that PTEN deficiency was associated with increased sensitivity to PI3K pathway inhibitors in selected cancer subtypes<sup>[101][102][103][104][105][106]</sup>. Although early clinical data indicated that PTEN loss was associated with improved response and survival in solid tumor patients treated with mTORC1 inhibitor, everolimus<sup>[107][108][109]</sup>, several phase II trials showed no clinical benefit of everolimus or temsirolimus treatment in patients with advanced solid tumors harboring PTEN loss<sup>[110][111][112]</sup>.

Several groups found that PTEN loss was generally associated with poor response to trastuzumab therapy, whether this agent was administered in the neoadjuvant, adjuvant, or metastatic settings<sup>[113][114][115][116][117]</sup>. Also, loss of PTEN expression in advanced colorectal cancer (CRC) has been linked with resistance to anti-EGFR mAbs like cetuximab and panitumumab<sup>[118][119][120][121][122][123]</sup>. Preclinical studies showed that loss of PTEN expression in EGFR mutant cells was associated with decreased sensitivity to EGFR TKIs, erlotinib and gefitinib<sup>[124][125]</sup>. Inhibition of the PI3K/AKT/mTOR signal pathway has been shown to be an effective strategy to radiosensitize NSCLC cells harboring the EGFR activating mutation that acquires resistance to both TKIs due to PTEN loss or inactivation mutations<sup>[126]</sup>. Loss or biallelic inactivation of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapies, including pembrolizumab and nivolumab in melanoma and leiomyosarcoma patients<sup>[127][128][129]</sup>.

PTEN loss of function mutation has been determined as an inclusion criterion for the trial evaluating olaparib efficacy in metastatic biliary tract cancer (NCT04042831); talazoparib efficacy in HER2-negative solid tumors (NCT02401347); rucaparib efficacy in prostate cancer (NCT02952534, NCT03533946), and niraparib efficacy in breast cancer (NCT04508803) or any malignancy (except prostate) cancer (NCT03207347). Clinical data also suggested that PTEN deficient cancers may be sensitive to olaparib<sup>[130]</sup>. However, in a phase II trial (NCT02286687), 13 patients with advanced solid tumors harboring PTEN mutation or loss (by IHC) had limited response to talazoparib treatment; only one patient with PTEN mutation had prolonged SD (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A096; NCT02286687). Besides, in a phase I trial (NCT00749502), no association between loss of PTEN expression and the efficacy of niraparib was identified in patients with castration-resistant prostate cancer<sup>[131]</sup>.

In a preclinical study, PTEN null cancer cells were sensitive to rucaparib treatment in vitro<sup>[132]</sup>.



# ACT Onco<sup>®</sup> + Report

## US FDA-APPROVED DRUG(S)

### Everolimus (AFINITOR)

Everolimus, a derivative of sirolimus, works as an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and blocks mTORC1-mediated downstream signals for cell growth, proliferation, and survival. Everolimus is developed and marketed by Novartis under the trade name AFINITOR.

### - FDA Approval Summary of Everolimus (AFINITOR)

<b>RADIANT-4</b> <sup>[133]</sup> NCT01524783	<b>Lung or gastrointestinal neuroendocrine tumor</b> (Approved on 2016/02/26)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 3.9]
<b>BOLERO-2</b> <sup>[134]</sup> NCT00863655	<b>Breast cancer</b> (Approved on 2012/07/20)
	<b>ER+/HER2-</b> Everolimus + exemestane vs. Placebo + exemestane [PFS(M): 7.8 vs. 3.2]
<b>EXIST-2</b> NCT00790400	<b>Tuberous sclerosis complex (tsc)-associated renal angiomyolipoma</b> (Approved on 2012/04/26)
	- Everolimus vs. Placebo [ORR(%): 41.8 vs. 0]
<b>RADIANT-3</b> <sup>[108]</sup> NCT00510068	<b>Pancreatic neuroendocrine tumor</b> (Approved on 2011/05/05)
	- Everolimus vs. Placebo [PFS(M): 11 vs. 4.6]
<b>EXIST-1</b> <sup>[135]</sup> NCT00789828	<b>Subependymal giant cell astrocytoma</b> (Approved on 2010/10/29)
	- Everolimus vs. Placebo [ORR(%): 35.0]
<b>RECORD-1</b> <sup>[136]</sup> NCT00410124	<b>Renal cell carcinoma</b> (Approved on 2009/05/30)
	- Everolimus vs. Placebo [PFS(M): 4.9 vs. 1.9]

### Niraparib (ZEJULA)

Niraparib is an oral, small molecule inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1 and -2 (PARP-1, -2). Niraparib is developed and marketed by Tesaro under the trade name ZEJULA.

### - FDA Approval Summary of Niraparib (ZEJULA)

<b>PRIMA</b> NCT02655016	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2020/04/29)
	- Niraparib vs. Placebo [PFS (overall population)(M): 13.8 vs. 8.2]
<b>NOVA</b> <sup>[137]</sup> NCT01847274	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/03/27)
	- Niraparib vs. Placebo [PFS (overall population)(M): 11.3 vs. 4.7]

# ACT Onco<sup>®</sup> + Report

## Olaparib (LYNPARZA)

Olaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase-1, -2, and -3 (PARP-1, -2, -3). Olaparib is developed by KuDOS Pharmaceuticals and marketed by AstraZeneca under the trade name LYNPARZA.

### - FDA Approval Summary of Olaparib (LYNPARZA)

<b>OlympiA</b> NCT02032823	<b>Her2-negative high-risk early breast cancer</b> (Approved on 2022/03/11)
	<b>HER2-/gBRCA mutation</b> Olaparib vs. Placebo [invasive disease-free survival (IDFS)(M): ]
<b>PROfound</b> <sup>[31]</sup> NCT02987543	<b>Prostate cancer</b> (Approved on 2020/05/19)
	<b>HRR genes mutation</b> Olaparib vs. Enzalutamide or abiraterone acetate [PFS(M): 5.8 vs. 3.5]
<b>PAOLA-1</b> <sup>[138]</sup> NCT02477644	<b>Ovarian cancer</b> (Approved on 2020/05/08)
	<b>HRD+</b> Olaparib + bevacizumab vs. Placebo + bevacizumab [PFS(M): 37.2 vs. 17.7]
<b>POLO</b> <sup>[139]</sup> NCT02184195	<b>Pancreatic adenocarcinoma</b> (Approved on 2019/12/27)
	<b>gBRCA mutation</b> Olaparib vs. Placebo [ORR(%): 23.0 vs. 12.0, PFS(M): 7.4 vs. 3.8]
<b>SOLO-1</b> <sup>[140]</sup> NCT01844986	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/12/19)
	<b>gBRCA mutation or sBRCA mutation</b> Olaparib vs. Placebo [PFS(M): NR vs. 13.8]
<b>OlympiAD</b> <sup>[141]</sup> NCT02000622	<b>Breast cancer</b> (Approved on 2018/02/06)
	<b>HER2-/gBRCA mutation</b> Olaparib vs. Chemotherapy [PFS(M): 7 vs. 4.2]
<b>SOLO-2/ENGOT-Ov21</b> <sup>[142]</sup> NCT01874353	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	<b>gBRCA mutation</b> Olaparib vs. Placebo [PFS(M): 19.1 vs. 5.5]
<b>Study19</b> <sup>[143]</sup> NCT00753545	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2017/08/17)
	- Olaparib vs. Placebo [PFS(M): 8.4 vs. 4.8]

## Rucaparib (RUBRACA)

Rucaparib is an inhibitor of the DNA repair enzyme poly (ADP-ribose) polymerase-1, -2 and -3 (PARP-1, -2, -3). Rucaparib is developed and marketed by Clovis Oncology under the trade name RUBRACA.

### - FDA Approval Summary of Rucaparib (RUBRACA)

<b>TRITON2</b> NCT02952534	<b>Prostate cancer</b> (Approved on 2020/05/15)
	<b>gBRCA mutation or sBRCA mutation</b> Rucaparib [ORR(%): 44.0, DOR(M): NE]
<b>ARIEL3</b> <sup>[42]</sup> NCT01968213	<b>Ovarian cancer, Fallopian tube cancer, Peritoneal carcinoma</b> (Approved on 2018/04/06)
	- Rucaparib vs. Placebo [PFS (All)(M): 10.8 vs. 5.4, PFS (HRD)(M): 13.6 vs. 5.4, PFS (tBRCA)(M): 16.6 vs. 5.4]

# ACT Onco<sup>®</sup> + Report

## Talazoparib (TALZENNA)

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1 and PARP2. Talazoparib is developed and marketed by Pfizer under the trade name TALZENNA.

### - FDA Approval Summary of Talazoparib (TALZENNA)

EMBRACA <sup>[144]</sup> NCT01945775	<b>Breast cancer</b> (Approved on 2018/10/16)
	<b>HER2-/gBRCA mutation</b>
	Talazoparib vs. Chemotherapy [PFS(M): 8.6 vs. 5.6]

## Tazemetostat (TAZVERIK)

Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat is developed and marketed by Epizyme under the trade name TAZVERIK.

### - FDA Approval Summary of Tazemetostat (TAZVERIK)

E7438-G000-101 NCT01897571	<b>Follicular lymphoma</b> (Approved on 2020/06/18)
	<b>EZH2 mutation</b>
	Tazemetostat (ezh2 mutant) vs. Tazemetostat (ezh2 wild-type) [ORR(%): 69.0 vs. 34.0, DOR(M): 10.9 vs. 13]
EZH-202 NCT02601950	<b>Epithelioid sarcoma</b> (Approved on 2020/01/23)
	<b>INI1 loss</b>
	Tazemetostat [ORR(%): 15.0]

## Temsirolimus (TORISEL)

Temsirolimus is a soluble ester of sirolimus (rapamycin, brand-name drug Rapamune) and functions as an inhibitor of mammalian target of rapamycin complex (mTORC). The inhibitory molecular mechanism is similar to Everolimus. Temsirolimus is developed by Wyeth Pharmaceuticals and marketed by Pfizer under the trade name TORISEL.

### - FDA Approval Summary of Temsirolimus (TORISEL)

[145] NCT00065468	<b>Renal cell carcinoma</b> (Approved on 2007/05/30)
	-
	Temsirolimus vs. Ifn- $\alpha$ [OS(M): 10.9 vs. 7.3]

D=day; W=week; M=month

# ACT Onco<sup>®</sup> + Report

## ONGOING CLINICAL TRIALS

Trials were searched by applying filters: study status, patient's diagnosis, intervention, location and/or biomarker(s). Please visit <https://clinicaltrials.gov> to search and view for a complete list of open available and updated matched trials.

No trial has been found.

# ACT Onco<sup>®</sup> + Report


## SUPPLEMENTARY INFORMATION OF TESTING RESULTS DETAILED INFORMATION OF VARIANTS WITH CLINICAL RELEVANCE

### - Single Nucleotide and Small InDel Variants

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
SMARCA4	R978*	21	c.2932C>T	NM_001128844	COSM1266239	39.3%	1519

### - Copy Number Alterations

Observed copy number (CN) for each evaluated position is shown on the y-axis. Regions referred to as amplification or deletion are shown in color. Regions without significant changes are represented in gray.



# ACT Onco<sup>®</sup> + Report

## OTHER DETECTED VARIANTS

Gene	Amino Acid Change	Exon	cDNA Change	Accession Number	COSMIC ID	Allele Frequency	Coverage
ADAMTSL1	R1322G	22	c.3964A>G	NM_001040272	-	46.9%	682
ETV4	P433L	13	c.1298C>T	NM_001079675	-	51.8%	952
MITF	V13A	1	c.38T>C	NM_198159	-	48.0%	1795
MUC16	D6322F	3	c.18964_18965delinsTT	NM_024690	-	48.2%	1198
SMARCA4	A1307P	29	c.3919G>C	NM_001128844	-	6.0%	1225
SMARCA4	R973Q	21	c.2918G>A	NM_001128844	COSM1161252	36.3%	1528
TSC2	L957W	26	c.2870T>G	NM_000548	-	50.0%	292

### Note:



- This table enlists variants detected by the panel other than those with clinical relevance (reported in Testing Result section). The clinical impact of a genetic variant is determined according to ACT Genomics in-house clinical knowledge database. A negative result does not necessarily indicate absence of biological effect on the tumor. Some variants listed here may possibly have preclinical data or may show potential clinical relevance in the future.



# ACT Onco<sup>®</sup> + Report

## TEST DETAILS

### SPECIMEN RECEIVED AND PATHOLOGY REVIEW



- Collection date: Aug 02, 2022
- Facility retrieved: 臺北榮總
- H&E-stained section No.: S11129483H
- Collection site: Prostate
- Examined by: Dr. Chien-Ta Chiang
  1. The percentage of viable tumor cells in total cells in the whole slide (%): 25%
  2. The percentage of viable tumor cells in total cells in the encircled areas in the whole slide (%): 60%
  3. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the whole slide (%): 0%
  4. The percentage of necrotic cells (including necrotic tumor cells) in total cells in the encircled areas in the whole slide (%): 0%
  5. Additional comment: NA
- Manual macrodissection: Performed on the highlighted region
- The outline highlights the area of malignant neoplasm annotated by a pathologist.

## RUN QC

- Panel: ACTOnco<sup>®</sup>+

### DNA test

- Mean Depth: 1008x
- Target Base Coverage at 100x: 95%

### RNA test

- Average unique RNA Start Sites per control GSP2: 154

## LIMITATIONS

1. This test does not provide information of variant causality and does not detect variants in non-coding regions that could affect gene expression. This report does not report polymorphisms and we do not classify whether a mutation is germline or somatic. Variants identified by this assay were not subject to validation by Sanger or other technologies.
2. The possibility cannot be excluded that certain pathogenic variants detected by other sequencing tools may not be reported in the test because of technical limitation of bioinformatics algorithm or the NGS sequencing platform, e.g. low coverage.
3. This test has been designed to detect fusions in 13 genes sequenced. Therefore, fusion in genes not covered by this test would not be reported. For novel fusions detected in this test, Sanger sequencing confirmation is recommended if residue specimen is available.

# ACT Onco<sup>®</sup> + Report

## NEXT-GENERATION SEQUENCING (NGS) METHODS

### DNA test

Extracted genomic DNA was amplified using primers targeting coding exons of analyzed genes and subjected to library construction. Barcoded libraries were subsequently conjugated with sequencing beads by emulsion PCR and enriched using Ion Chef system. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific).

Raw reads generated by the sequencer were mapped to the hg19 reference genome using the Ion Torrent Suite. Coverage depth was calculated using Torrent Coverage Analysis plug-in. Single nucleotide variants (SNVs) and short insertions/deletions (InDels) were identified using the Torrent Variant Caller plug-in. VEP (Variant Effect Predictor) was used to annotate every variant using databases from Clinvar, COSMIC and Genome Aggregation database. Variants with coverage  $\geq 20$ , allele frequency  $\geq 5\%$  and actionable variants with allele frequency  $\geq 2\%$  were retained. This test provides uniform coverage of the targeted regions, enabling target base coverage at  $100\times \geq 85\%$  with a mean coverage  $\geq 500\times$ .

Variants reported in Genome Aggregation database with  $> 1\%$  minor allele frequency (MAF) were considered as polymorphisms. ACT Genomics in-house database was used to determine technical errors. Clinically actionable and biologically significant variants were determined based on the published medical literature.

The copy number alterations (CNAs) were predicted as described below:

Amplicons with read counts in the lowest 5th percentile of all detectable amplicons and amplicons with a coefficient of variation  $\geq 0.3$  were removed. The remaining amplicons were normalized to correct the pool design bias. ONCOCNV (an established method for calculating copy number aberrations in amplicon sequencing data by Boeva et al., 2014) was applied for the normalization of total amplicon number, amplicon GC content, amplicon length, and technology-related biases, followed by segmenting the sample with a gene-aware model. The method was used as well for establishing the baseline of copy number variations.

Tumor mutational burden (TMB) was calculated by using the sequenced regions of ACTOnco<sup>®</sup> to estimate the number of somatic nonsynonymous mutations per megabase of all protein-coding genes (whole exome). The TMB calculation predicted somatic variants and applied a machine learning model with a cancer hotspot correction. TMB may be reported as "TMB-High", "TMB-Low" or "Cannot Be Determined". TMB-High corresponds to  $\geq 7.5$  mutations per megabase (Muts/Mb); TMB-Low corresponds to  $< 7.5$  Muts/Mb. TMB is reported as "Cannot Be Determined" if the tumor purity of the sample is  $< 30\%$ .

Classification of microsatellite instability (MSI) status is determined by a machine learning prediction algorithm. The change of a number of repeats of different lengths from a pooled microsatellite stable (MSS) baseline in  $> 400$  genomic loci are used as the features for the algorithm. The final output of the results is either microsatellite Stable (MSS) or microsatellite instability high (MSI-H).

### RNA test

Extracted RNA was reverse-transcribed and subjected to library construction. Sequencing was performed according to Ion Proton or Ion S5 sequencer protocol (Thermo Fisher Scientific). To ensure sequencing quality for fusion variant analysis, the average unique RNA Start Sites (SS) per control Gene Specific Primer 2 (GSP 2) should be  $\geq 10$ .

The fusion analysis pipeline aligned sequenced reads to the human reference genome, identified regions that map to noncontiguous regions of the genome, applied filters to exclude probable false-positive events and, annotated previously characterized fusion events according to Quiver Gene Fusion Database, a curated database owned and maintained by ArcherDX. In general, samples with detectable fusions need to meet the following criteria: (1) Number of unique start sites (SS) for the GSP2  $\geq 3$ ; (2) Number of supporting reads spanning the fusion junction  $\geq 5$ ; (3) Percentage of supporting reads spanning the fusion junction  $\geq 10\%$ ; (4) Fusions annotated in Quiver Gene Fusion Database.

# ACT Onco<sup>®</sup> + Report

## DATABASE USED

- Reference genome: Human genome sequence hg19
- COSMIC v.92
- Genome Aggregation database r2.1.1
- ClinVar (version 20210404)
- ACT Genomics in-house database
- Quiver Gene Fusion Database version 5.1.18

## Variant Analysis:

醫檢師陳韻鈺 博士  
Yun-Yu Chen Ph.D.  
檢字第 015647 號

Yun Yu Chen

## Sign Off

解剖病理專科醫師王業翰  
Yeh-Han Wang M.D.  
病解字第 000545 號

Yeh

# ACT Onco<sup>®</sup> + Report

## GENE LIST SNV & CNV

ABCB1*	ABCC2*	ABCG2*	ABL1	ABL2	ADAMTS1	ADAMTS13	ADAMTS15	ADAMTS16	ADAMTS18	ADAMTS6	ADAMTS9
ADAMTSL1	ADGRA2	ADH1C*	AKT1	AKT2	AKT3	ALDH1A1*	ALK	AMER1	APC	AR	ARAF
ARID1A	ARID1B	ARID2	ASXL1	ATM	ATR	ATRX	AURKA	AURKB	AXIN1	AXIN2	AXL
B2M	BAP1	BARD1	BCL10	BCL2*	BCL2L1	BCL2L2*	BCL6	BCL9	BCOR	BIRC2	BIRC3
BLM	BMPR1A	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2*	BTB	BUB1B	CALR
CANX	CARD11	CASP8	CBFB	CBL	CCNA1	CCNA	CCNB1	CCNB2	CCNB3	CCND1	CCND2
CCND3	CCNE1	CCNE2	CCNH	CD19	CD274	CD58	CD70*	CD79A	CD79B	CDC73	CDH1
CDK1	CDK12	CDK2	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDKN1A	CDKN1B	CDKN2A
CDKN2B	CDKN2C	CEBPA*	CHEK1	CHEK2	CIC	CREBBP	CRKL	CRLF2	CSF1R	CTCF	CTLA4
CTNNA1	CTNNB1	CUL3	CYLD	CYP1A1*	CYP2B6*	CYP2C19*	CYP2C8*	CYP2D6	CYP2E1*	CYP3A4*	CYP3A5*
DAXX	DCUN1D1	DDR2	DICER1	DNMT3A	DOT1L	DPYD	DTX1	E2F3	EGFR	EP300	EPCAM
EPHA2	EPHA3	EPHA5	EPHA7	EPHB1	ERBB2	ERBB3	ERBB4	ERCC1	ERCC2	ERCC3	ERCC4
ERCC5	ERG	ESR1	ESR2	ETV1	ETV4	EZH2	FAM46C	FANCA	FANCC	FANCD2	FANCE
FANCF	FANCG	FANCL	FAS	FAT1	FBXW7	FCGR2B	FGF1*	FGF10	FGF14	FGF19*	FGF23
FGF3	FGF4*	FGF6	FGFR1	FGFR2	FGFR3	FGFR4	FH	FLCN	FLT1	FLT3	FLT4
FOXL2*	FOXP1	FRG1	FUBP1	GATA1	GATA2	GATA3	GNA11	GNA13	GNAQ	GNAS	GREM1
GRIN2A	GSK3B	GSTP1*	GSTT1*	HGF	HIF1A	HIST1H1C*	HIST1H1E*	HNF1A	HR	HRAS*	HSP90AA1
HSP90AB1	HSPA4	HSPA5	IDH1	IDH2	IFNL3*	IGF1	IGF1R	IGF2	IKBK	IKBKE	IKZF1
IL6	IL7R	INPP4B	INSR	IRF4	IRS1	IRS2*	JAK1	JAK2	JAK3	JUN*	KAT6A
KDM5A	KDM5C	KDM6A	KDR	KEAP1	KIT	KMT2A	KMT2C	KMT2D	KRAS	LCK	LIG1
LIG3	LMO1	LRP1B	LYN	MALT1	MAP2K1	MAP2K2	MAP2K4	MAP3K1	MAP3K7	MAPK1	MAPK3
MAX	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1	MET	MITF	MLH1	MPL	MRE11
MSH2	MSH6	MTHFR*	MTOR	MUC16	MUC4	MUC6	MUTYH	MYC	MYCL	MYCN	MYD88
NAT2*	NBN	NEFH	NF1	NF2	NFE2L2	NFKB1	NFKBIA	NKX2-1*	NOTCH1	NOTCH2	NOTCH3
NOTCH4	NPM1	NQO1*	NRAS	NSD1	NTRK1	NTRK2	NTRK3	PAK3	PALB2	PARP1	PAX5
PAX8	PBRM1	PDCD1	PDCD1LG2	PDGFRA	PDGFRB	PDIA3	PGF	PHOX2B*	PIK3C2B	PIK3C2G	PIK3C3
PIK3CA	PIK3CB	PIK3CD	PIK3CG	PIK3R1	PIK3R2	PIK3R3	PIM1	PMS1	PMS2	POLB	POLD1
POLE	PPARG	PPP2R1A	PRDM1	PRKAR1A	PRKCA	PRKCB	PRKCG	PRKCI	PRKCQ	PRKDC	PRKN
PSMB8	PSMB9	PSME1	PSME2	PSME3	PTCH1	PTEN	PTGS2	PTPN11	PTPRD	PTPRT	RAC1
RAD50	RAD51	RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	RECQL4
REL	RET	RHOA	RICTOR	RNF43	ROS1	RPPH1	RPTOR	RUNX1	RUNX1T1	RXRA	SDHA
SDHB	SDHC	SDHD	SERPINB3	SERPINB4	SETD2	SF3B1	SGK1	SH2D1A*	SLC19A1*	SLC22A2*	SLC1B1*
SLC1B3*	SMAD2	SMAD3	SMAD4	SMARCA4	SMARCB1	SMO	SOC1*	SOX2*	SOX9	SPEN	SPOP
SRC	STAG2	STAT3	STK11	SUFU	SYK	SYNE1	TAF1	TAP1	TAP2	TAPBP	TBX3
TEK	TERT	TET1	TET2	TGFBR2	TMSB4X*	TNF	TNFAIP3	TNFRSF14	TNFSF11	TOP1	TP53
TPMT*	TSC1	TSC2	TSHR	TYMS	U2AF1	UBE2A*	UBE2K	UBR5	UGT1A1*	USH2A	VDR*
VEGFA	VEGFB	VHL	WT1	XIAP	XPO1	XRCC2	ZNF217				

\*Analysis of copy number alterations NOT available.

## FUSION

ALK	BRAF	EGFR	FGFR1	FGFR2	FGFR3	MET	NRG1	NTRK1	NTRK2	NTRK3	RET	ROS1
-----	------	------	-------	-------	-------	-----	------	-------	-------	-------	-----	------


# ACT Onco<sup>®</sup> + Report

## APPENDIX

### POSSIBLE THERAPEUTIC IMPLICATIONS FOR HETEROZYGOUS DELETION


Gene	Therapies	Possible effect
<i>FBXW7</i>	Everolimus, Temsirolimus	<b>sensitive</b>
<i>ATM</i>	Niraparib, Olaparib, Rucaparib, Talazoparib	<b>sensitive</b>
<i>CHEK1</i>	Niraparib, Olaparib, Rucaparib, Talazoparib	<b>sensitive</b>
<i>MRE11</i>	Niraparib, Olaparib, Rucaparib, Talazoparib	<b>sensitive</b>
<i>FBXW7</i>	Gefitinib, Regorafenib	<b>resistant</b>

### SIGNALING PATHWAYS AND MOLECULAR-TARGETED AGENTS



#### 1: Everolimus, Temsirolimus

# ACT Onco<sup>®</sup> + Report



1: Olaparib, Niraparib, Rucaparib, Talazoparib



# ACT Onco<sup>®</sup> + Report

## DISCLAIMER

### 法律聲明

本檢驗報告僅提供專業醫療參考，結果需經專業醫師解釋及判讀。基因突變資訊非必具備藥物或治療有效性指標，反之亦然。本檢驗報告提供之用藥指引不聲明或保證其臨床有效性，反之亦然。本基因檢測方法係由本公司研究開發，已經過有效性測試。

本檢驗報告非經本公司許可，不得私自變造、塗改，或以任何方式作為廣告及其他宣傳之用途。

本公司於提供檢驗報告後，即已完成本次契約義務，後續之報告解釋、判讀及用藥、治療，應自行尋求相關專業醫師協助，若需將報告移件其他醫師，本人應取得該醫師同意並填寫移件申請書，主動告知行動基因，行動基因僅能配合該醫師意願與時間提供醫師解說。

### 醫療決策需由醫師決定

任何治療與用藥需經由醫師在考慮病患所有健康狀況相關資訊包含健檢、其他檢測報告和病患意願後，依照該地區醫療照護標準由醫師獨立判斷。醫師不應僅依據單一報告結果(例如本檢測或本報告書內容)做決策。

### 基因突變與用藥資訊並非依照有效性排序

本報告中列出之生物標記變異與藥物資訊並非依照潛在治療有效性排序。

### 證據等級

藥物潛在臨床效益(或缺乏潛在臨床效益)的實證證據是依據至少一篇臨床療效個案報告或臨床前試驗做為評估。本公司盡力提供適時及準確之資料，但由於醫學科技之發展日新月異，本公司不就本報告提供的資料是否為準確、適宜或最新作保證。

### 責任

本檢驗報告僅提供專業醫療參考，本公司及其員工不對任何由使用本報告之內容引起的直接、間接、特殊、連帶或衍生的損失或損害承擔責任。

# ACT Onco<sup>®</sup> + Report

## REFERENCE

1. PMID: 10078207; 1999, Mol Cell;3(2):247-53  
Reconstitution of a core chromatin remodeling complex from SWI/SNF subunits.
2. PMID: 23568486; 2013, Nat Rev Genet;14(5):347-59  
From neural development to cognition: unexpected roles for chromatin.
3. PMID: 25387058; 2015, Annu Rev Pathol;10():145-71  
SWI/SNF chromatin remodeling and human malignancies.
4. PMID: 17637742; 2008, Oncogene;27(4):460-8  
Characterization of mammary tumors from Brg1 heterozygous mice.
5. PMID: 23644491; 2013, Nat Genet;45(6):592-601  
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.
6. PMID: 25060813; 2014, Acta Neuropathol;128(3):453-6  
SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis.
7. PMID: 23143597; 2012, Nat Genet;44(12):1321-5  
The genetic landscape of mutations in Burkitt lymphoma.
8. PMID: 20137775; 2010, Am J Hum Genet;86(2):279-84  
Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.
9. PMID: 24658002; 2014, Nat Genet;46(5):438-43  
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.
10. PMID: 24658004; 2014, Nat Genet;46(5):424-6  
Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.
11. PMID: 24658001; 2014, Nat Genet;46(5):427-9  
Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.
12. PMID: 28292935; 2017, Mol Cancer Ther;16(5):850-860  
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models.
13. PMID: 26671993; 2016, Clin Cancer Res;22(10):2396-404  
SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
14. PMID: 26260527; 2015, Cancer Res;75(19):4176-87  
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
15. PMID: 22079189; 2012, Trends Biochem Sci;37(1):15-22  
The ATM protein kinase and cellular redox signaling: beyond the DNA damage response.
16. PMID: 1548942; 1992, Leukemia;6 Suppl 1():8-13  
Cancer susceptibility in ataxia-telangiectasia.
17. PMID: 12810666; 2003, Cancer Res;63(12):3325-33  
Contributions of ATM mutations to familial breast and ovarian cancer.
18. PMID: 1961222; 1991, N Engl J Med;325(26):1831-6  
Incidence of cancer in 161 families affected by ataxia-telangiectasia.
19. PMID: 28779002; 2017, J Med Genet;54(11):732-741

# ACT Onco<sup>®</sup> + Report

Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks.

20. PMID: 16400190; 2006, Carcinogenesis;27(4):848-55  
Atm-haploinsufficiency enhances susceptibility to carcinogen-induced mammary tumors.
21. PMID: 29478780; 2018, Am J Hum Genet;102(3):401-414  
Inherited DNA-Repair Defects in Colorectal Cancer.
22. PMID: 9488043; 1998, Oncogene;16(6):789-96  
ATM is usually rearranged in T-cell prolymphocytic leukaemia.
23. PMID: 11429421; 2001, J Clin Pathol;54(7):512-6  
Ataxia telangiectasia gene mutations in leukaemia and lymphoma.
24. PMID: 11756177; 2002, Blood;99(1):238-44  
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
25. PMID: 21993670; 2012, Haematologica;97(1):47-55  
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
26. PMID: 22981675; 2013, Eur Urol;63(5):920-6  
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
27. PMID: 22410096; 2012, Oral Oncol;48(8):698-702  
Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma.
28. PMID: 23103869; 2012, Nature;491(7424):399-405  
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.
29. PMID: 18948947; 2008, Nature;455(7216):1069-75  
Somatic mutations affect key pathways in lung adenocarcinoma.
30. PMID: 30537493; 2019, Hum Pathol;86():85-92  
Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
31. PMID: 32343890; 2020, N Engl J Med;382(22):2091-2102  
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
32. PMID: 26510020; 2015, N Engl J Med;373(18):1697-708  
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
33. PMID: 31806540; 2020, Lancet Oncol;21(1):162-174  
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
34. PMID: 26282658; 2015, J Clin Oncol;33(33):3858-65  
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
35. PMID: 29103871; 2017, Lancet Oncol;18(12):1637-1651  
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
36. PMID: 33119476; 2020, J Clin Oncol;38(36):4274-4282  
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
37. PMID: 32086346; 2020, Clin Cancer Res;26(11):2487-2496  
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.

# ACT Onco<sup>®</sup> + Report

38. PMID: 20739657; 2010, Blood;116(22):4578-87  
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
39. PMID: 31699977; 2019, Nat Commun;10(1):5065  
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
40. PMID: 34503215; 2021, Cancers (Basel);13(17):  
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.
41. PMID: 23881923; 2013, Clin Cancer Res;19(18):5003-15  
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
42. PMID: 28916367; 2017, Lancet;390(10106):1949-1961  
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
43. PMID: 26238431; 2015, Eur Urol;68(6):959-67  
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
44. PMID: 22420423; 2012, Breast Cancer Res;14(2):R47  
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
45. PMID: 23154512; 2012, Oncotarget;3(11):1348-55  
Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.
46. PMID: 12781359; 2003, Cancer Cell;3(5):421-9  
Chk1 and Chk2 kinases in checkpoint control and cancer.
47. PMID: 15261141; 2004, Cancer Cell;6(1):45-59  
Chk1 is haploinsufficient for multiple functions critical to tumor suppression.
48. PMID: 15539958; 2005, Cell Cycle;4(1):131-9  
Chk1 is essential for tumor cell viability following activation of the replication checkpoint.
49. PMID: 15459660; 2004, Nat Rev Mol Cell Biol;5(10):792-804  
Checking on DNA damage in S phase.
50. PMID: 22585575; 2012, J Clin Invest;122(6):2165-75  
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
51. PMID: 17638866; 2007, Cancer Res;67(14):6574-81  
The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas.
52. PMID: 17848589; 2007, Mol Cell Proteomics;6(12):2150-64  
A proteomics analysis of cell signaling alterations in colorectal cancer.
53. PMID: 24418519; 2014, J Surg Res;187(1):6-13  
Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
54. PMID: 15297395; 2004, Clin Cancer Res;10(15):4944-58  
Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays.
55. PMID: 21458083; 2011, Trends Pharmacol Sci;32(5):308-16  
Anticancer therapy with checkpoint inhibitors: what, where and when?
56. PMID: 15498494; 2004, Curr Biol;14(20):1852-7  
A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size.

# ACT Onco<sup>®</sup> + Report

57. PMID: 15103331; 2004, EMBO J;23(10):2116-25  
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7.
58. PMID: 16023596; 2005, Cancer Cell;8(1):25-33  
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase.
59. PMID: 11533444; 2001, Science;294(5540):173-7  
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase.
60. PMID: 11461910; 2001, J Biol Chem;276(38):35847-53  
The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog.
61. PMID: 11425854; 2001, J Biol Chem;276(37):34371-8  
Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor.
62. PMID: 16863506; 2006, Cancer Sci;97(8):729-36  
Fbw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
63. PMID: 18787170; 2008, Science;321(5895):1499-502  
FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.
64. PMID: 20484041; 2010, Cancer Res;70(11):4728-38  
The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation.
65. PMID: 21368833; 2011, Nature;471(7336):104-9  
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.
66. PMID: 18094723; 2008, Nat Rev Cancer;8(2):83-93  
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation.
67. PMID: 23032637; 2012, Cancer Inform;11():157-71  
Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach.
68. PMID: 24586741; 2014, PLoS One;9(2):e89388  
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
69. PMID: 24360397; 2014, Lung Cancer;83(2):300-1  
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation.
70. PMID: 27399335; 2017, Oncogene;36(6):787-796  
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
71. PMID: 25860929; 2015, Oncotarget;6(11):9240-56  
FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
72. PMID: 29633504; 2018, Mol Oncol;12(6):883-895  
FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
73. PMID: 28522751; 2017, Cancer Res;77(13):3527-3539  
Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
74. PMID: 24884509; 2014, Mol Cancer;13():110  
Fbw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
75. PMID: 19910469; 2010, J Biol Chem;285(2):1097-104  
MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX.

# ACT Onco<sup>®</sup> + Report

76. PMID: 20655309; 2010, FEBS Lett;584(17):3682-95  
The MRN complex in double-strand break repair and telomere maintenance.
77. PMID: 24894818; 2014, Breast Cancer Res;16(3):R58  
Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
78. PMID: 23755103; 2014, PLoS One;8(6):e63313  
Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A.
79. PMID: 11196167; 2001, Cancer Res;61(1):23-6  
Alterations of the double-strand break repair gene MRE11 in cancer.
80. PMID: 11850399; 2002, EMBO Rep;3(3):248-54  
Human MRE11 is inactivated in mismatch repair-deficient cancers.
81. PMID: 16959974; 2006, Science;314(5797):268-74  
The consensus coding sequences of human breast and colorectal cancers.
82. PMID: 24927325; 2014, PLoS One;9(6):e100041  
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
83. PMID: 21300766; 2011, Cancer Res;71(7):2632-42  
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
84. PMID: 25310185; 2014, PLoS One;9(10):e108483  
MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.
85. PMID: 17218262; 2007, Cell;128(1):157-70  
Essential role for nuclear PTEN in maintaining chromosomal integrity.
86. PMID: 18794879; 2008, Oncogene;27(41):5443-53  
PTEN: a new guardian of the genome.
87. PMID: 18767981; 2009, Annu Rev Pathol;4():127-50  
PTEN and the PI3-kinase pathway in cancer.
88. PMID: 21125671; 2011, J Pathol;223(2):137-46  
Haplo-insufficiency: a driving force in cancer.
89. PMID: 11553783; 2001, Proc Natl Acad Sci U S A;98(20):11563-8  
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.
90. PMID: 20400965; 2010, Nat Genet;42(5):454-8  
Subtle variations in Pten dose determine cancer susceptibility.
91. PMID: 9467011; 1998, Hum Mol Genet;7(3):507-15  
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation.
92. PMID: 24136893; 2013, J Natl Cancer Inst;105(21):1607-16  
Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria.
93. PMID: 21430697; 2011, Nat Rev Cancer;11(4):289-301  
PTEN loss in the continuum of common cancers, rare syndromes and mouse models.
94. PMID: 18455982; 2008, Cell;133(3):403-14  
Tenets of PTEN tumor suppression.



# ACT Onco<sup>®</sup> + Report

95. PMID: 9393738; 1997, Cancer Res;57(23):5221-5  
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
96. PMID: 9829719; 1998, Clin Cancer Res;4(11):2577-83  
Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
97. PMID: 9582022; 1998, Oncogene;16(13):1743-8  
Analysis of PTEN and the 10q23 region in primary prostate carcinomas.
98. PMID: 9671321; 1998, Oncogene;17(1):123-7  
Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas.
99. PMID: 11504908; 2001, Proc Natl Acad Sci U S A;98(18):10314-9  
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
100. PMID: 23714559; 2013, Am Soc Clin Oncol Educ Book;():  
Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
101. PMID: 20231295; 2010, J Biol Chem;285(20):14980-9  
Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
102. PMID: 23287563; 2013, Clin Cancer Res;19(7):1760-72  
Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models.
103. PMID: 17047067; 2006, Cancer Res;66(20):10040-7  
Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.
104. PMID: 22422409; 2012, Clin Cancer Res;18(6):1777-89  
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
105. PMID: 22662154; 2012, PLoS One;7(5):e37431  
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
106. PMID: 23136191; 2012, Clin Cancer Res;18(24):6771-83  
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
107. PMID: 27091708; 2016, J Clin Oncol;34(18):2115-24  
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
108. PMID: 21306238; 2011, N Engl J Med;364(6):514-23  
Everolimus for advanced pancreatic neuroendocrine tumors.
109. PMID: 23582881; 2013, Eur Urol;64(1):150-8  
Phase 2 trial of single-agent everolimus in chemotherapy-naïve patients with castration-resistant prostate cancer (SAKK 08/08).
110. PMID: 28330462; 2017, BMC Cancer;17(1):211  
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.
111. PMID: 27016228; 2016, Gynecol Oncol;141(1):43-8  
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
112. PMID: 26951309; 2016, J Clin Oncol;34(14):1660-8  
Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

# ACT Onco<sup>®</sup> + Report

113. PMID: 15324695; 2004, Cancer Cell;6(2):117-27  
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
114. PMID: 20813970; 2010, Am J Pathol;177(4):1647-56  
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
115. PMID: 21135276; 2011, J Clin Oncol;29(2):166-73  
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
116. PMID: 21594665; 2011, Breast Cancer Res Treat;128(2):447-56  
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
117. PMID: 17936563; 2007, Cancer Cell;12(4):395-402  
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
118. PMID: 18700047; 2008, BMC Cancer;8():234  
Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.
119. PMID: 17940504; 2007, Br J Cancer;97(8):1139-45  
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.
120. PMID: 19398573; 2009, J Clin Oncol;27(16):2622-9  
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
121. PMID: 19953097; 2010, Br J Cancer;102(1):162-4  
PTEN status in advanced colorectal cancer treated with cetuximab.
122. PMID: 27605871; 2016, World J Gastroenterol;22(28):6345-61  
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
123. PMID: 24666267; 2014, Acta Oncol;53(7):852-64  
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
124. PMID: 19351834; 2009, Cancer Res;69(8):3256-61  
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
125. PMID: 23133538; 2012, PLoS One;7(10):e48004  
Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
126. PMID: 23592446; 2013, J Cell Biochem;114(6):1248-56  
mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
127. PMID: 26645196; 2016, Cancer Discov;6(2):202-16  
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
128. PMID: 28228279; 2017, Immunity;46(2):197-204  
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
129. PMID: 30150660; 2018, Nat Genet;50(9):1271-1281  
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
130. PMID: 21468130; 2011, Nat Rev Clin Oncol;8(5):302-6  
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
131. PMID: 23810788; 2013, Lancet Oncol;14(9):882-92  
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-

# ACT Onco<sup>®</sup> + Report

escalation trial.

132. PMID: 23565244; 2013, PLoS One;8(4):e60408  
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
133. PMID: 26703889; 2016, Lancet;387(10022):968-977  
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
134. PMID: 22149876; 2012, N Engl J Med;366(6):520-9  
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
135. PMID: 23158522; 2013, Lancet;381(9861):125-32  
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
136. PMID: 18653228; 2008, Lancet;372(9637):449-56  
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
137. PMID: 27717299; 2016, N Engl J Med;375(22):2154-2164  
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
138. PMID: 31851799; 2019, N Engl J Med;381(25):2416-2428  
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
139. PMID: 31157963; 2019, N Engl J Med;381(4):317-327  
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
140. PMID: 30345884; 2018, N Engl J Med;379(26):2495-2505  
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
141. PMID: 28578601; 2017, N Engl J Med;377(6):523-533  
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
142. PMID: 28754483; 2017, Lancet Oncol;18(9):1274-1284  
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
143. PMID: 27617661; 2016, Lancet Oncol;17(11):1579-1589  
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
144. PMID: 30110579; 2018, N Engl J Med;379(8):753-763  
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
145. PMID: 17538086; 2007, N Engl J Med;356(22):2271-81  
Temsilolimus, interferon alfa, or both for advanced renal-cell carcinoma.